Rifaximin effective for repeat treatment of IBS with diarrhea

December 27, 2016

(HealthDay)—Repeat treatment with the nonsystemic antibiotic rifaximin is effective in patients with relapsing symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D), according to a study published in the December issue of Gastroenterology.

Anthony Lembo, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues conducted a multicenter, phase 3, randomized, placebo-controlled trial to evaluate the safety and efficacy of repeat with the nonsystemic antibiotic rifaximin (550 mg three times daily for two weeks) among 636 adults with IBS-D, mean and bloating scores of 3 or more, and loose stool (February 2012 through June 2014).

The researchers found that the percentage of responders was significantly greater with rifaximin than placebo (P = 0.03). For abdominal pain, the percentage of responders (P = 0.018) was significantly greater with rifaximin versus placebo, but not for stool consistency (P = 0.42). There were also significant improvements for prevention of recurrence, durable response, and urgency. The groups had similar adverse event rates.

"In a phase 3 study of patients with relapsing symptoms of IBS-D, repeat rifaximin treatment was efficacious and well tolerated," the authors write.

Several authors disclosed financial ties to Salix Pharmaceuticals, which manufactures rifaximin and funded the study.

Explore further: Low-dose rifaximin cuts endotoxin level in cirrhosis

More information: Full Text

Related Stories

Low-dose rifaximin cuts endotoxin level in cirrhosis

October 29, 2015
(HealthDay)—For patients with liver cirrhosis, low-dose rifaximin is comparable to high-dose rifaximin for reducing serum endotoxin levels, according to a study published online Oct. 16 in the Journal of Digestive Diseases.

FDA approves new drugs for irritable bowel syndrome

May 28, 2015
(HealthDay)—Two new drugs for adults with irritable bowel syndrome with diarrhea (IBS-D) were approved by the U.S. Food and Drug Administration on Wednesday.

Relamorelin beneficial in adults with diabetic gastroparesis

July 7, 2016
(HealthDay)—For adults with diabetic gastroparesis, relamorelin reduces vomiting frequency and severity and accelerates gastric emptying, according to a study published in the July issue of Gastroenterology.

Targeted antibiotic drug safest among recommended treatments for irritable bowel disease

November 2, 2011
Among the most commonly used treatments for irritable bowel syndrome – which affects as many as 20 percent of the United States population – a targeted antibiotic was shown to be the safest in a new study by Cedars-Sinai ...

Recommended for you

New hope for cystic fibrosis

October 19, 2018
A new triple-combination drug treatment being trialled at the Mater Hospital in Brisbane could increase the life expectancy of patients with cystic fibrosis.

Bug guts shed light on Central America Chagas disease

October 18, 2018
In Central America, Chagas disease, or American trypanosomiasis, is spread by the "kissing bug" Triatoma dimidiata. By collecting DNA from the guts of these bugs, researchers reporting in PLOS Neglected Tropical Diseases ...

Rapid genomic sequencing of Lassa virus in Nigeria enabled real-time response to 2018 outbreak

October 18, 2018
Mounting a collaborative, real-time response to a Lassa fever outbreak in early 2018, doctors and scientists in Nigeria teamed up with researchers at Broad Institute of MIT and Harvard and colleagues to rapidly sequence the ...

Researchers cure drug-resistant infections without antibiotics

October 17, 2018
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria ...

Infectious disease consultation significantly reduces mortality of patients with bloodstream yeast infections

October 17, 2018
In a retrospective cohort study conducted at the University of Alabama at Birmingham Division of Infectious Diseases, patients with candidemia—a yeast infection in the bloodstream—had more positive outcomes as they relate ...

How drug resistant TB evolved and spread globally

October 17, 2018
The most common form of Mycobacterium tuberculosis (TB) originated in Europe and spread to Asia, Africa and the Americas with European explorers and colonialists, reveals a new study led by UCL and the Norwegian Institute ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.